Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Inventiva S.A.NASDAQ: IVA

Revenue · Q4 FY2025 · quarter ended Dec 2025

Revenue declines year over year

Q4 FY2025 revenue of €28.79K fell 99.6% year over year. Over 3 fiscal years it compounded at -28.3% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 9 analysts of €3.68M (-17.9%) for the fiscal year ending Dec 2026, a step up from the -51.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
€28.79K— QoQ
Last fiscal yearDec 2025
€4.48M-51.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.6%——
1 year-51.3%-17.9%+33.4 pp
3-year CAGR-28.3%+206.5%+234.8 pp
5-year CAGR+168.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

EUR · from the income statement

Latest · FY2025
4.48M EUR
Year-over-year change
-51.3%
4-year CAGR
+1.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -51.3% is the 5th highest of 7, against a peer median of +10.2%.
  • Over three fiscal years its annual growth of -28.3% compares with a peer median of -8.8%.
IVA Competitors
Revenue for IVA and competitors
Company Period LTM YoY 3-year CAGR
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$69.21M USD+7.4%-8.8%
IVVDInvivyd, Inc.LTM Mar 2026$55.87M USD+52.3%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.72M USD+1033.9%+111.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.2M USD+13.0%-7.0%
IVAInventiva S.A.FY2025€4.48M EUR-51.3%-28.3%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$1.78M USD-94.8%-70.7%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$225K USD——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$59K USD-86.6%-85.2%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$0 USD——
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$0 USD——
Peer median (excluding IVA) —+10.2%-8.8%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.19M12.18M17.48M9.2M4.48M
Cost of Revenue1.02M995K(23K)3.88M2.8M
Gross Profit4.19M17.06M17.5M9.2M1.51M
Gross Margin100.0%140.1%100.1%100.0%33.7%
Research & Development48.45M60.47M110.01M90.88M83.61M
Selling, General & Admin11.52M15.5M15.61M17.1M53.89M
Operating Expenses56.31M74.17M120.19M106.76M137.37M
Depreciation & Amortization858K870K2.6M5.2M2.8M
EBITDA(52.76M)(56.29M)(102.04M)(166.53M)(128.15M)
EBITDA Margin-1258.0%-462.2%-583.9%-1810.4%-2858.6%
Operating Income(52.11M)(57.11M)(102.71M)(97.56M)(130.95M)
Operating Margin-1242.6%-468.9%-587.7%-1060.6%-2921.0%
Interest Income57K390K945K1.14M2.83M
Interest Expense138K707K5.18M12.18M32.3M
Other Income / Expenses2.84M2.82M(7.11M)(86.34M)(211.38M)
Income Before Tax(49.27M)(54.29M)(109.82M)(183.9M)(342.33M)
Pre-Tax Margin-1174.8%-445.8%-628.4%-1999.4%-7636.1%
Income Tax Expense364K(20K)607K313K22K
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Net Margin-1183.5%-445.6%-631.8%-2002.7%-7587.8%
EPS (Basic)(1.27)(1.31)(2.43)(3.54)(1.82)
EPS (Diluted)(1.27)(1.31)(2.43)(3.54)(1.82)
Weighted Avg Shares39.17M41.45M45.35M51.98M186.8M
Weighted Avg Shares (Diluted)39.17M41.45M45.35M51.98M186.8M

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.